GH3 - GEROVITAL Articles (VI)
Treatment in Osteoarthritis
by Mircea Dumitru M.D., PhD.
1946, Aslan published her first research on Novocaine (1). In 1951,
she studied the effect of procaine on experimental arthritis (2).
the first results with Novocaine injections, I tried this treatment
on patients with arthritis and those with a tendency to ankylosis.
Because these diseases are chronic, I administered novocaine for each
patient with more injections. With great joy, I noticed an improvement
in the local symptoms, and even more importantly a great improvement
in their overall general condition. Before the treatment, the patients
avoided any movement due to pain and now they were willing and wanting
to walk, sitting up to read and talking. The biggest reward was noticing
an increase in their interest in life and for their family".
remembered, too: "On April 15, 1949- an American GI, with arthritis
arrived in my clinic. He had terrible pains and his articulations
were blocked. I explained to him my ideas about novocaine and after
receiving his permission, I gave him an intra-arterial injection with
1-% novocaine. After 10 to 15 minutes, his knee was mobile and he
could flex his leg outright. What happiness! I administered his treatment
for a further two weeks and he was completely recovered" (3).
(5,6,7,8,9) and experimental studies (2,10) previously conducted by
Aslan et al. have pointed out the effects of Gerovital-H3®
therapy in arthritis. Concerning the chronic degenerating disease
under the effect of the eutrophic Gerovital-H3® treatment, an
obvious amelioration of the clinical signs was particularly noticed
in osteoarticulary diseases (11,12,13). In a study performed in 1982
(4) on 2643 patients, Aslan noticed that it became evident that pains
ceased in 62.2% of the patients, and articulary mobility and periarticulary
muscular tonus were ameliorated in 51.8% of the cases. Repeated radiological
examinations indicated a gradual amelioration of osteoporosis and
other dystrophic osteoarticulary modifications.
conducted a study on 100 elderly patients admitted to the National
Institute of Gerontology and Geriatrics (NIGG) in Bucharest. They
were aged 60 to 89 and suffering from moderate to severe arthritis
involving one or more joints. Two groups of 50 patients were made
up being very similar in age, sex and rheumatic diseases.
both groups, arthritis involved more often the spine than the peripheral
joints, in which hip-arthritis was slightly less prevalent than knee-arthritis,
the latter being more frequent in women than men did. Patients with
severe organ or system pathology were not included. No patient with
abarticular rheumatism was included in the groups under study, nor
patients with clinical, paraclinical or radiological signs suggesting
another type of rheumatism, nor those having a positive test for the
rheumatoid arthritis. I noted a significant number of patients suffered
from Heberdenosis, which was much more frequent in women than in men.
reasons for admission of the patients included pains in the affected
joints, limitation of movements, myalgia, joint swelling and declining
muscular strength. The patients under study were divided into the
following clinical forms who display joint pains persisting at rest;
moderate limitation of movements (with 10% to 30% of the normal joint
movement capacity; accompanying phenomena which point to 'warm up'
arthritis processes-rubor, swelling, heat; reduction of joint space
and the presence of osteophytes (diagnosed radiologically). Severe
forms with marked pains; who display over 30% deficits of joint function;
marked joint swelling; a certain degree of invalidity that forced
the patient to use an aid such as a stick or frame- for walking.
the patients displayed reduction of joint space and osteophytosis.
distribution of these two clinical forms was sensibly equal.
far as associated morbidity of the patients is concerned, the obvious
prevalence of cardio-vascular diseases was first followed in order
by neuro-psychiatric, respiratory and digestive complaints.
treatment was administered to the patients in the first group as follows:
one i. m. injection daily in the morning for 18 days, followed by
12 days of Gerovital-H3® pills, twice
daily: 9:00 A.M. and 4:00 P.M. Similarly, the patients in the second
group received Placebo injections and pills. No other drug was given,
nor any local therapy applied.
efficacy was assessed by comparing prior and post-treatment values
of the following parameters recorded in all patients of the two groups:
as a subjective parameter and its characteristics;
joint mobility assessed by goniometry and movements based on tests
specific to each joint;
muscular tone by muscular check-up;
accompanying phenomena: joint swelling, instability, crepitations;
overall functional capacity of joints affected by arthritis.
Some parameters reflecting the patients' general condition such as
arterial blood pressure, cyrcadian rhythms and psychic state were
also checked in parallel. In the two groups (Gerovital-H3® and
Placebo) the clinical signs of progress was recorded as the following:
group the following was recorded:
A remarkable alleviation in 34% of cases, satisfactory alleviation
in 54% of cases and no effect in just 12% of the cases;
Joint Mobility: Improved in 56% of cases and remaining unchanged in
Muscular Tone: Improved in 41% of cases and no change in the rest.
I didn't notice any side effects during the treatment with Gerovital-H3®.
the Placebo group:
A satisfactory alleviation in only 11% of cases and no influence upon
the remaining ones;
Joint Mobility: Improved in only 4% of cases and there was no change
for the rest;
Muscular Tone: Unchanged in 100% of the patients.
symptoms dominated by pain and limitation of movements was positively
influenced in the case of the first group of patients, (i.e. those
under Gerovital-H3® treatment). Their psychic condition was obviously
improved. The small amount of positive outcomes recorded in the patients
from the second group, (i.e. the Placebo group) by the slight alleviation
of joint pains can be explained in terms of the patients resting while
hospitalized, which is likely to have diminished the degree of pain
studies carried out at the National Institute of Gerontology and Geriatrics
in Bucharest have proved that Gerovital-H3® exerts a beneficial
effect on the vascular, nervous and metabolic components involved
in the genesis of degenerative rheumatism (4,6,7,8,10,11,12). The
positive properties of Gerovital-H3®
treatment can be explained as:
antalgo action either controlling or reducing the pain caused by irritation
of the nervous network from the spongious or by osteophitic presence;
The anti-inflammatory effect exerted through the AMPc, stimulated
by the moderate rise in circulating catecholamine levels;
Improvement of capillary permeability and the favourable intervention
in the bioenzymatic disorders at the level of the joint cartilage
considered primum movens in the process of joint degeneration.
Gerovital-H3® can be the drug of choice in the management of arthritis
in Geriatrics, because of its beneficial effects on the distressing,
sometimes invalidating clinical phenomena and because of its paucity
of side effects.
Doses, contra-indications and side effects were described in the Gerovital-H3®
monography of October 1998. Please ask for a copy if you have not
A., Rosenzweig S.: L'action de la novocaine injectee hans la veine
chez l'homme. Bull. Acad. Med. Roumaine, 1946, 7, p. 891-900.
Aslan A. et al.: The effects of procaine on experimental arthritis
induced in albino rats. Com. Acad. Romainia, 1950. 1, 11-12, p. 1110-1116.
Aslan A. et al.: Intra-atrerial treatment with procaine in arthritis.
Bull. St. Acad. Bucharest, 1950, II, 7, p. 891.
Aslan A. et al.: Peculiarities of chronic degenerative rheumatism
in the aged and the efficiency of Gerovital-H3® therapy. Romanian
J. Geront. & Geriatrics, 1982, 3, 1, 3-13.
Aslan A., David C.: Ergebnisse der Novocainbehandlung-Stoff H3- bei
dysmetabolischen Arthropathien. Therapie Woche-Karlsruhe, 1957, 8,
Aslan A.: Longitudinal Study in the National Institute of Gerontology
& Geriatrics of Romania. J. Geront. & Geriatrics. 1980, 1,
Aslan A. et al.: The Parenteral Therapy with Gerovital-H3® in
the Aged with Degenerative Rheumatism. Romanian J. Geront. & Geriatrics.
1983, 4, 3, 151-158.
Barsan M., Rodica P.: Cervical Spondylodiskarthrosis in the Elderly
and Gerovital-H3® Treatment. Romanian J. Geront. & Geriatrics.
1985, 6, 1, 35-42.
Aslan A.: The Therapeutics of Old Age. The Action of Procaine. Congr.
of the Intern. Assoc. of Geront., 1960, San Francisco. Medical and
Clinical Aspects of Aging. H. T. Blumenthal, Ed., Columbia Univ. Press,
New York, USA, 1962, 4, p. 272-292.
Matei V.Cet al.: The Effects of Gerovital-H3® Treatment on Antigen-Induced
Arthritis in Rabbits. Romanian J. Geront. & Geriatrics. 1984,
5, 1, 55-63.
Aslan A., David C. et al.: Gerovital-H3® Original Product. Ed.
Ministry of Chemical Industry. Bucharest, 1977.
Aslan A.: Theoretical Bases of Procaine Therapy in the 'Prophilaxis
of Ageing. Romainan J. Geront. Geriatrics. 1980, 1, 1, 5-15.
Dumitru M. et al.: Double Blind Study on Gerovital-H3® Treatment
in the Elderly with Arthritis. Romanian J. Geront. Geriatrics. 1985,
6, 4, 257-263.
THE FOLLOWING ARTICLE IS EXTRACTED FROM THE COPYRIGHT PROTECTED
INTERNATIONAL ANTIAGING SYSTEMS BULLETIN. IT IS INTENDED FOR PRIVATE
VIEWING ONLY AND CANNOT BE COPIED WITHOUT THE WRITTEN PERMISSION
OF IAS. DISCLAIMER: ALL INFORMATION IS EDUCATIONAL AND PROVIDED
UNDER IAS TERMS & CONDITIONS. IT DOES NOT, AND SHOULD NOT, REPLACE
THE ADVICE OF YOUR PHYSICIAN